Understanding how cell death affects heart injury after blood flow is restored

Mitochondria-mediated mechanisms of ferroptosis in response to cardiac ischemia-reperfusion injury

['FUNDING_OTHER'] · UNIVERSITY OF PUERTO RICO MED SCIENCES · NIH-11034437

This study is looking at how a specific type of cell death in heart cells happens after blood flow returns to the heart following a heart attack, and it aims to find ways to protect those cells and improve treatments for heart conditions.

Quick facts

Phase['FUNDING_OTHER']
Study typeNih_funding
SexAll
SponsorUNIVERSITY OF PUERTO RICO MED SCIENCES (nih funded)
Locations1 site (SAN JUAN, UNITED STATES)
Trial IDNIH-11034437 on ClinicalTrials.gov

What this research studies

This research investigates the mechanisms behind a specific type of cell death called ferroptosis that occurs in heart cells following ischemia-reperfusion injury, which is when blood supply returns to the heart after a period of deprivation. The study aims to clarify how mitochondria, the energy-producing structures in cells, contribute to this process and how they can be targeted to reduce heart damage. By examining the role of certain molecules and proteins involved in ferroptosis, the research seeks to identify new therapeutic strategies to protect heart muscle cells during recovery from heart attacks. Patients may benefit from insights gained that could lead to improved treatments for heart conditions.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals who have experienced myocardial infarction or are at high risk for coronary heart disease.

Not a fit: Patients with non-cardiac related conditions or those who have not experienced ischemia-reperfusion injury may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new therapies that significantly reduce heart damage after heart attacks.

How similar studies have performed: While the specific focus on ferroptosis in cardiac injury is relatively novel, there is growing evidence that targeting cell death pathways can improve outcomes in heart disease.

Where this research is happening

SAN JUAN, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.

View on NIH RePORTER →

Conditions: Coronary Disease

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.